Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
Seer and Korea University presented preliminary data at ASMS 2026 demonstrating the Proteograph platform's ability to enable AI-driven multi-cancer screening through deep plasma proteomics. The analysis covered more than 5,500 plasma samples across ten major cancer types, achieving coverage of more than 14,000 protein groups per sample with high reproducibility.
Key figures
- Cancer types
- ten
- Total samples planned
- more than 20,000
- Plasma samples analyzed
- more than 5,500
- Protein groups per sample
- averaging more than 14,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.